16 September 2026 editorial review · Trial
TIRTLE1 low-dose tirzepatide in adults with T1D and obesity: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Sources for this record: Tirzepatide in Type 1 Diabetes — Cardiometabolic Effects (TIRTLE1) (registry); Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial (peer-reviewed).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.
Selected cell-therapy and adjunct trial review — 16 September 2026
Outcome and correction: Existing numerical outcomes and safety counts retained after primary full-text check. Added important exclusions (recent DKA/severe hypoglycemia, gastroparesis, pancreatitis, retinopathy and pregnancy).
Primary sources checked: Primary full text, PMC12719702; DOI.
Limits: Twenty-four randomized, 22 completed, 12 weeks; inadequate to exclude uncommon harms. ANZCTR eligibility corroborated by primary paper rather than a fresh registry extraction.